Primary IgA nephropathy : FDA grants full approval to Travere Therapeutics’ Filspari

Pallavi Madhiraju- September 8, 2024

In a groundbreaking move, the US Food and Drug Administration (FDA) has granted full approval to Travere Therapeutics' Filspari (sparsentan) for treating primary IgA nephropathy ... Read More

FDA grants Otsuka’s Sibeprenlimab breakthrough therapy designation in IgAN

Pallavi Madhiraju- February 17, 2024

In a significant development for the treatment of kidney disease, the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sibeprenlimab, an ... Read More